查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2141750

iPS細胞服務市場：全球市場預測，2026-2032年

iPSC Service Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，iPS 細胞服務市場將成長至 16.8 億美元，複合年成長率為 7.42%。

主要市場統計數據
基準年 2025 10.1億美元
預計年份：2026年 10.8億美元
預測年份 2032 16.8億美元
複合年成長率 (%) 7.42%

iPSC 服務：執行摘要和策略背景

誘導多能幹細胞 (iPSC) 服務支持再程式化、細胞株表徵、分化、疾病建模、藥物發現、毒性測試和轉化研究。儘管該領域結合了細胞生物學的進步和日益標準化的實驗流程，但品質、可重複性、供體知情同意、遺傳穩定性以及監管文件仍然是推廣應用的核心挑戰。

標準化和轉化研究正在重塑iPSC服務。

產業趨勢正從為學術研究量身定做的方案轉向高度可重複、有據可查且擴充性的服務交付。買家越來越需要檢驗的工作流程、明確的發布標準、可追溯的材料、可靠的品管系統以及能夠支援臨床前決策的資料包。雖然自動化、基因組編輯、類器官建構、冷凍保存和多體學的進步正在拓展應用範圍，但倫理管治和長期的樣本溯源管理正成為關鍵的差異化因素。

人工智慧正在加速設計、分析和品管。

人工智慧正在影響iPSC服務的整體，包括實驗設計、影像分析、細胞狀態分類、分化最佳化以及高維度資料集的解讀。機器學習可以幫助識別形態模式、預測實驗方案的性能並確定候選條件的優先級，但其價值取決於具有代表性的訓練數據、嚴格的檢驗、可解釋性以及對批次相關偏差的控制。各機構應將人工智慧視為決策支援層，而非實驗檢驗的替代品，並與實驗室專業知識結合。

區域洞察：基礎設施差異，強而有力的科學合作

北美受益於成熟的生物醫學研究基礎設施、專業的服務供應商以及學術界與生物技術產業之間的緊密合作。歐洲將先進的轉化研究與嚴格的資料保護、倫理和品質文件要求相結合。亞太地區受益於不斷擴大的生物製造能力、活躍的研究以及對細胞模型日益成長的需求。中東正透過組織結構建設和戰略投資來發展研究能力，而非洲則面臨基礎設施和人才方面的限制，儘管在疾病相關研究領域存在一些機會。拉丁美洲正透過大學主導的計畫和區域間合作取得進展，但資金、專用設備和標準化工作流程的取得仍然是關鍵問題。

集團洞察：政策協調和跨境合作至關重要。

在東南亞國協，基礎設施和監管成熟度的差異使得通用通用協議和加強區域能力建設至關重要。金磚國家在科學、臨床實踐和製造領域擁有強大的實力，但在准入、標準和管治方面存在差異。歐盟強調研究原則、隱私權保護和品管系統的協調統一。七國集團（G7）國家普遍擁有強大的科研生態系統，並對先進的轉化研究和監管框架抱有很高的期望。海灣合作理事會（GCC）國家正透過協調投資和國際夥伴關係來加強其生物醫學能力。北約成員國利用其緊密的科研網路和合作潛力，但在處理敏感資料和遵守國家合規要求方面需要謹慎管理。

國家洞察：獨特能力塑造服務需求

美國和加拿大擁有強大的轉化醫學生態系統和專業的科學研究基礎設施。英國、德國、法國、義大利和西班牙已建立生物醫學研究能力，歐洲的數據、倫理和品質要求對其運作產生重要影響。日本和韓國在再生醫學、細胞生物學和先進實驗室技術領域處於領先地位。中國在不斷完善的管治架構下，正積極拓展其科研和生物製造能力。印度擁有大規模的科研人口和蓬勃發展的生物技術產業。澳洲將強大的生命科學研究與地理位置分散的研究機構結合。巴西和墨西哥是拉丁美洲重要的研究中心，而俄羅斯雖然在監管、採購和合作方面有其自身的考量，但仍保持強大的科學研究實力。

iPSC 服務領導者的可執行優先事項

領導者應建立一套透明的品管體系，涵蓋捐贈者知情同意、身分驗證、無菌性、遺傳穩定性、分化性能以及控制鏈。服務也應模組化，以便客戶在不影響可比性的前提下選擇再程式化、表徵、分化、篩檢或資料分析等要素。對自動化和人工智慧的投資必須輔以檢驗、人工監督、網路安全和書面性能標準。跨站點參考材料、標準化元資料和可互通的報告結構可以緩解可重複性問題。最後，與醫院、大學、生物製藥研究人員和監管機構夥伴關係，可以明確轉化應用的證據要求，同時增強疾病相關性。

調查方法：基於證據的iPSC服務環境評估

本執行摘要對誘導多能幹細胞（iPSC）服務活動進行了系統評估，包括再程式化、表徵、分化、疾病建模、篩檢、品管和數據分析。評估結果按地區和跨國集團進行分類，重點在於基礎設施、研究生態系統、法規、人才和合作條件方面的差異。評估優先考慮已公開記錄的科學、監管、組織和技術方面的進步，並區分成熟實踐和新興應用。本報告未使用任何市場規模估算、市場佔有率、預測或公司特定聲明。

結論：可重複性和轉化研究應對力是決定優越性的決定性因素。

隨著研究方向轉向更貼近人類的模型、可擴展的實驗以及基於證據的轉化工作流程，iPSC服務的價值日益凸顯。為了在長期競爭中佔據優勢地位，必須將生物學專業知識與嚴格的品管、安全的數據管理、強大的自動化以及經過充分檢驗的人工智慧相結合。儘管區域和國家差異需要根據具體情況制定靈活的交付模式，但通用的優先事項卻很明確：來源清晰、可重複、互通性、符合倫理管治以及與下游研究決策的顯著相關性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 iPS 蜂窩服務市場：依服務類型分類

  • 銀行服務
    • 細胞庫
    • iPSC銀行
  • 特徵描述服務
    • 基因組特徵分析
    • 表現型特徵
    • 品管
  • 差異化服務
    • 心肌細胞
    • 肝細胞
    • 神經元
  • 基因改造服務
    • CRISPR
    • TALEN
    • ZFN
  • 再程式化服務
    • 無需整合
      • 微型RNA
      • 低分子化合物
    • 非病毒載體
      • 附加質體
      • mRNA
      • 蛋白質
    • 病毒載體
      • 慢病毒
      • 逆轉錄病毒
      • 仙台病毒

第8章 iPS 細胞服務市場：再程式化法分類

  • 無需整合
    • 微型RNA
    • 低分子化合物
  • 非病毒載體
    • 附加質體
    • mRNA
    • 蛋白質
  • 病毒載體
    • 慢病毒
    • 逆轉錄病毒
    • 仙台病毒

第9章 iPS 蜂窩服務市場：按蜂窩類型分類

  • 心肌細胞
  • 內皮細胞
  • 肝細胞
  • 神經元
  • 胰島BETA細胞

第10章 iPS 細胞服務市場：依應用分類

  • 細胞療法
    • 同種異體移植療法
    • 自體細胞療法
  • 化妝品測試
    • 抗衰老測試
    • 皮膚刺激性測試
  • 疾病模型
    • 癌症建模
    • 遺傳疾病建模
    • 感染疾病建模
  • 藥物發現
    • 先導化合物的鑑定
    • 先導藥物最適化
    • 篩檢
  • 再生醫學
    • 細胞療法
    • 組織工程
  • 毒性測試
    • 體外毒理學
    • 安全藥理學

第11章 iPS 蜂窩服務市場：以最終用戶分類

  • 學術研究機構
  • 生技公司
  • 受託研究機構
  • 製藥公司

第12章 iPS 細胞服務市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 iPS 細胞服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 iPS 細胞服務市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AMSBIO LLC
  • Applied StemCell, Inc.
  • Axol Bioscience Ltd.
  • Bio-Techne Corporation
  • Cell Guidance Systems Ltd.
  • Creative Bioarray
  • Evotec SE
  • FUJIFILM Cellular Dynamics, Inc.
  • GenScript Biotech Corporation
  • Gentarget Inc.
  • Lonza Group AG
  • Ncardia AG
  • Neuromics, Inc.
  • OriGene Technologies, Inc.
  • Pluriomics BV
  • PromoCell GmbH
  • REPROCELL Inc.
  • Sino Biological Inc.
  • STEMCELL Technologies Inc.
  • System Biosciences, LLC
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

第17章 主要專家

Product Code: MRR-9C4233EE5E6E

The iPSC Service Market is projected to grow by USD 1.68 billion at a CAGR of 7.42% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.01 billion
Estimated Year [2026] USD 1.08 billion
Forecast Year [2032] USD 1.68 billion
CAGR (%) 7.42%

iPSC Services: Executive Summary and Strategic Context

Induced pluripotent stem cell (iPSC) services support reprogramming, cell-line characterization, differentiation, disease modeling, drug discovery, toxicity testing, and translational research. The field connects advances in cellular biology with increasingly standardized laboratory workflows, while quality, reproducibility, donor consent, genetic stability, and regulatory documentation remain central to adoption.

Standardization and Translation Are Reshaping iPSC Services

The landscape is shifting from bespoke academic protocols toward more reproducible, documented, and scalable service delivery. Buyers increasingly require validated workflows, defined release criteria, traceable materials, dependable quality systems, and data packages that can support preclinical decisions. Progress in automation, genome editing, organoid development, cryopreservation, and multi-omics is broadening applications, while ethical governance and long-term sample provenance are becoming essential differentiators.

Artificial Intelligence Is Accelerating Design, Analysis, and Quality Control

Artificial intelligence is affecting iPSC services across experimental planning, image analysis, cell-state classification, differentiation optimization, and interpretation of high-dimensional datasets. Machine learning can help identify morphological patterns, predict protocol performance, and prioritize candidate conditions, but its value depends on representative training data, rigorous validation, explainability, and controls against batch-related bias. Organizations should treat AI as a decision-support layer integrated with laboratory expertise, rather than as a substitute for experimental verification.

Regional Insights: Uneven Infrastructure, Strong Scientific Connectivity

North America benefits from mature biomedical research infrastructure, specialized service providers, and strong links between academia and biotechnology. Europe combines advanced translational research with demanding requirements for data protection, ethics, and quality documentation. Asia-Pacific is supported by expanding biomanufacturing capabilities, substantial research activity, and growing demand for cell-based models. The Middle East is developing research capacity through institution building and strategic investment, while Africa faces infrastructure and talent constraints alongside targeted opportunities in disease-relevant research. Latin America is advancing through university-led programs and regional collaborations, with access to capital, specialized equipment, and standardized workflows remaining important considerations.

Group Insights: Policy Alignment and Cross-Border Collaboration Matter

ASEAN economies show varied levels of infrastructure and regulatory maturity, making shared protocols and regional capability building valuable. BRICS members contribute substantial scientific, clinical, and manufacturing capacity but differ in access, standards, and governance approaches. The European Union emphasizes harmonized research principles, privacy safeguards, and quality systems. G7 countries generally combine strong research ecosystems with sophisticated translational and regulatory expectations. GCC states are strengthening biomedical capabilities through coordinated investment and international partnerships. NATO members benefit from dense research networks and collaboration potential, although sensitive data handling and national compliance requirements must be managed carefully.

Country Insights: Distinct Capabilities Shape Service Demand

The United States and Canada offer strong translational ecosystems and specialized research infrastructure. The United Kingdom, Germany, France, Italy, and Spain contribute established biomedical research capacity, with European data, ethics, and quality requirements shaping operations. Japan and South Korea are prominent in regenerative medicine, cell biology, and advanced laboratory technology. China is expanding research and biomanufacturing capabilities under evolving governance frameworks. India is supported by a large scientific workforce and growing biotechnology activity. Australia combines strong life-science research with geographically distributed institutions. Brazil and Mexico provide important Latin American research bases, while Russia retains scientific capabilities alongside distinct regulatory, procurement, and collaboration considerations.

Actionable Priorities for iPSC Service Leaders

Leaders should establish transparent quality systems covering donor consent, identity, sterility, genetic stability, differentiation performance, and chain of custody. They should modularize services so customers can select reprogramming, characterization, differentiation, screening, or data-analysis components without sacrificing comparability. Investment in automation and AI should be paired with validation, human oversight, cybersecurity, and documented performance thresholds. Cross-site reference materials, standardized metadata, and interoperable reporting can reduce reproducibility problems. Finally, partnerships with hospitals, universities, biopharma researchers, and regulators can improve disease relevance while clarifying evidence requirements for translational use.

Research Methodology: Evidence-Based Assessment of the iPSC Service Landscape

This executive summary uses a structured assessment of iPSC service activities, including reprogramming, characterization, differentiation, disease modeling, screening, quality control, and data analysis. Findings are organized by geography and multinational group to identify differences in infrastructure, research ecosystems, regulation, workforce, and collaboration conditions. The assessment prioritizes publicly documented scientific, regulatory, institutional, and technology developments and separates established practices from emerging applications. No market estimates, market shares, forecasts, or company-specific claims are used.

Conclusion: Reproducibility and Translational Readiness Define Advantage

iPSC services are becoming more valuable as research moves toward human-relevant models, scalable experimentation, and evidence-based translational workflows. The strongest long-term position will come from combining biological expertise with rigorous quality management, secure data practices, robust automation, and carefully validated AI. Regional and country differences make adaptable delivery models essential, but common priorities remain clear: provenance, reproducibility, interoperability, ethical governance, and demonstrable relevance to downstream research decisions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. iPSC Service Market, by Service Type

  • 7.1. Introduction
  • 7.2. Banking Service
    • 7.2.1. Cell Banking
    • 7.2.2. iPSC Banking
  • 7.3. Characterization Service
    • 7.3.1. Genomic Characterization
    • 7.3.2. Phenotypic Characterization
    • 7.3.3. Quality Control
  • 7.4. Differentiation Service
    • 7.4.1. Cardiomyocytes
    • 7.4.2. Hepatocytes
    • 7.4.3. Neurons
  • 7.5. Genetic Modification Service
    • 7.5.1. CRISPR
    • 7.5.2. TALEN
    • 7.5.3. ZFN
  • 7.6. Reprogramming Service
    • 7.6.1. Integration-Free
      • 7.6.1.1. MicroRNA
      • 7.6.1.2. Small Molecules
    • 7.6.2. Non-Viral Vector
      • 7.6.2.1. Episomal Plasmid
      • 7.6.2.2. mRNA
      • 7.6.2.3. Protein
    • 7.6.3. Viral Vector
      • 7.6.3.1. Lentivirus
      • 7.6.3.2. Retrovirus
      • 7.6.3.3. Sendai Virus

8. iPSC Service Market, by Reprogramming Method

  • 8.1. Introduction
  • 8.2. Integration-Free
    • 8.2.1. MicroRNA
    • 8.2.2. Small Molecules
  • 8.3. Non-Viral Vector
    • 8.3.1. Episomal Plasmid
    • 8.3.2. mRNA
    • 8.3.3. Protein
  • 8.4. Viral Vector
    • 8.4.1. Lentivirus
    • 8.4.2. Retrovirus
    • 8.4.3. Sendai Virus

9. iPSC Service Market, by Cell Type

  • 9.1. Introduction
  • 9.2. Cardiomyocytes
  • 9.3. Endothelial Cells
  • 9.4. Hepatocytes
  • 9.5. Neurons
  • 9.6. Pancreatic Beta Cells

10. iPSC Service Market, by Application

  • 10.1. Introduction
  • 10.2. Cell Therapy
    • 10.2.1. Allogeneic Therapy
    • 10.2.2. Autologous Therapy
  • 10.3. Cosmetics Testing
    • 10.3.1. Anti-Aging Testing
    • 10.3.2. Skin Irritation Testing
  • 10.4. Disease Modeling
    • 10.4.1. Cancer Modeling
    • 10.4.2. Genetic Disease Modeling
    • 10.4.3. Infectious Disease Modeling
  • 10.5. Drug Discovery
    • 10.5.1. Lead Identification
    • 10.5.2. Lead Optimization
    • 10.5.3. Screening
  • 10.6. Regenerative Medicine
    • 10.6.1. Cell Therapy
    • 10.6.2. Tissue Engineering
  • 10.7. Toxicology Testing
    • 10.7.1. In Vitro Toxicology
    • 10.7.2. Safety Pharmacology

11. iPSC Service Market, by End User

  • 11.1. Introduction
  • 11.2. Academic Research Institutes
  • 11.3. Biotechnology Companies
  • 11.4. Contract Research Organizations
  • 11.5. Pharmaceutical Companies

12. iPSC Service Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. iPSC Service Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. iPSC Service Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AMSBIO LLC
  • 16.2. Applied StemCell, Inc.
  • 16.3. Axol Bioscience Ltd.
  • 16.4. Bio-Techne Corporation
  • 16.5. Cell Guidance Systems Ltd.
  • 16.6. Creative Bioarray
  • 16.7. Evotec SE
  • 16.8. FUJIFILM Cellular Dynamics, Inc.
  • 16.9. GenScript Biotech Corporation
  • 16.10. Gentarget Inc.
  • 16.11. Lonza Group AG
  • 16.12. Ncardia AG
  • 16.13. Neuromics, Inc.
  • 16.14. OriGene Technologies, Inc.
  • 16.15. Pluriomics B.V.
  • 16.16. PromoCell GmbH
  • 16.17. REPROCELL Inc.
  • 16.18. Sino Biological Inc.
  • 16.19. STEMCELL Technologies Inc.
  • 16.20. System Biosciences, LLC
  • 16.21. Takara Bio Inc.
  • 16.22. Thermo Fisher Scientific Inc.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global iPSC Service Market, Years Considered for the Study
  • FIGURE 2. Global iPSC Service Market, Research Design
  • FIGURE 3. Global iPSC Service Market, Research Framework
  • FIGURE 4. Global iPSC Service Market, Data Triangulation
  • FIGURE 5. Global iPSC Service Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global iPSC Service Market Size, by Service Type, 2025 vs 2032 (%)
  • FIGURE 7. Global iPSC Service Market Size, by Service Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global iPSC Service Market Size, by Reprogramming Method, 2025 vs 2032 (%)
  • FIGURE 9. Global iPSC Service Market Size, by Reprogramming Method, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global iPSC Service Market Size, by Cell Type, 2025 vs 2032 (%)
  • FIGURE 11. Global iPSC Service Market Size, by Cell Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global iPSC Service Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 13. Global iPSC Service Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global iPSC Service Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global iPSC Service Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global iPSC Service Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global iPSC Service Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global iPSC Service Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global iPSC Service Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global iPSC Service Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global iPSC Service Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global iPSC Service Market Segmentation & Coverage
  • TABLE 2. Global iPSC Service Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global iPSC Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 4. Global Banking Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Banking Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Banking Service Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Cell Banking Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Cell Banking Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Cell Banking Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global iPSC Banking Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global iPSC Banking Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global iPSC Banking Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Characterization Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Characterization Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Characterization Service Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Genomic Characterization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Genomic Characterization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Genomic Characterization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Phenotypic Characterization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Phenotypic Characterization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Phenotypic Characterization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Quality Control Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Quality Control Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Quality Control Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Differentiation Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Differentiation Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Differentiation Service Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Cardiomyocytes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Cardiomyocytes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Cardiomyocytes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Hepatocytes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Hepatocytes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Hepatocytes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Neurons Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Neurons Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Neurons Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Genetic Modification Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Genetic Modification Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Genetic Modification Service Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global CRISPR Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global CRISPR Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global CRISPR Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global TALEN Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global TALEN Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global TALEN Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global ZFN Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global ZFN Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global ZFN Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Reprogramming Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Reprogramming Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Reprogramming Service Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Integration-Free Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Global Integration-Free Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 54. Global Integration-Free Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 55. Global MicroRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global MicroRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global MicroRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Small Molecules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Small Molecules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Small Molecules Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Non-Viral Vector Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Non-Viral Vector Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Non-Viral Vector Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Episomal Plasmid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Episomal Plasmid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Episomal Plasmid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global mRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global mRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global mRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Protein Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Global Protein Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. Global Protein Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 73. Global Viral Vector Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global Viral Vector Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global Viral Vector Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global Lentivirus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Global Lentivirus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. Global Lentivirus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 79. Global Retrovirus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Global Retrovirus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 81. Global Retrovirus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 82. Global Sendai Virus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 83. Global Sendai Virus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 84. Global Sendai Virus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 85. Global iPSC Service Market Size, by Reprogramming Method, 2017-2032 (USD Million)
  • TABLE 86. Global Integration-Free Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Global Integration-Free Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. Global Integration-Free Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 89. Global MicroRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Global MicroRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. Global MicroRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 92. Global Small Molecules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 93. Global Small Molecules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 94. Global Small Molecules Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 95. Global Non-Viral Vector Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. Global Non-Viral Vector Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 97. Global Non-Viral Vector Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 98. Global Episomal Plasmid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 99. Global Episomal Plasmid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 100. Global Episomal Plasmid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 101. Global mRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 102. Global mRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. Global mRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 104. Global Protein Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 105. Global Protein Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 106. Global Protein Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 107. Global Viral Vector Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 108. Global Viral Vector Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 109. Global Viral Vector Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 110. Global Lentivirus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 111. Global Lentivirus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 112. Global Lentivirus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 113. Global Retrovirus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 114. Global Retrovirus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 115. Global Retrovirus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 116. Global Sendai Virus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 117. Global Sendai Virus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 118. Global Sendai Virus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 119. Global iPSC Service Market Size, by Cell Type, 2017-2032 (USD Million)
  • TABLE 120. Global Cardiomyocytes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 121. Global Cardiomyocytes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 122. Global Cardiomyocytes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 123. Global Endothelial Cells Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 124. Global Endothelial Cells Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 125. Global Endothelial Cells Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 126. Global Hepatocytes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 127. Global Hepatocytes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 128. Global Hepatocytes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 129. Global Neurons Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 130. Global Neurons Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 131. Global Neurons Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 132. Global Pancreatic Beta Cells Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 133. Global Pancreatic Beta Cells Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 134. Global Pancreatic Beta Cells Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 135. Global iPSC Service Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 136. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 137. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 138. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 139. Global Allogeneic Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 140. Global Allogeneic Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 141. Global Allogeneic Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 142. Global Autologous Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 143. Global Autologous Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 144. Global Autologous Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 145. Global Cosmetics Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 146. Global Cosmetics Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 147. Global Cosmetics Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 148. Global Anti-Aging Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 149. Global Anti-Aging Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 150. Global Anti-Aging Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 151. Global Skin Irritation Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 152. Global Skin Irritation Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 153. Global Skin Irritation Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 154. Global Disease Modeling Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 155. Global Disease Modeling Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 156. Global Disease Modeling Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 157. Global Cancer Modeling Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 158. Global Cancer Modeling Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 159. Global Cancer Modeling Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 160. Global Genetic Disease Modeling Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 161. Global Genetic Disease Modeling Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 162. Global Genetic Disease Modeling Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 163. Global Infectious Disease Modeling Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 164. Global Infectious Disease Modeling Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 165. Global Infectious Disease Modeling Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 166. Global Drug Discovery Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 167. Global Drug Discovery Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 168. Global Drug Discovery Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 169. Global Lead Identification Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 170. Global Lead Identification Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 171. Global Lead Identification Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 172. Global Lead Optimization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 173. Global Lead Optimization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 174. Global Lead Optimization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 175. Global Screening Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 176. Global Screening Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 177. Global Screening Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 178. Global Regenerative Medicine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 179. Global Regenerative Medicine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 180. Global Regenerative Medicine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 181. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 182. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 183. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 184. Global Tissue Engineering Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 185. Global Tissue Engineering Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 186. Global Tissue Engineering Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 187. Global Toxicology Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 188. Global Toxicology Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 189. Global Toxicology Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 190. Global In Vitro Toxicology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 191. Global In Vitro Toxicology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 192. Global In Vitro Toxicology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 193. Global Safety Pharmacology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 194. Global Safety Pharmacology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 195. Global Safety Pharmacology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 196. Global iPSC Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 197. Global Academic Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 198. Global Academic Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 199. Global Academic Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 200. Global Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 201. Global Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 202. Global Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 203. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 204. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 205. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 206. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 207. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 208. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 209. Global iPSC Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 210. Asia-Pacific iPSC Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 211. Asia-Pacific iPSC Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 212. Asia-Pacific iPSC Service Market Size, by Banking Service, 2017-2032 (USD Million)
  • TABLE 213. Asia-Pacific iPSC Service Market Size, by Characterization Service, 2017-2032 (USD Million)
  • TABLE 214. Asia-Pacific iPSC Service Market Size, by Differentiation Service, 2017-2032 (USD Million)
  • TABLE 215. Asia-Pacific iPSC Service Market Size, by Genetic Modification Service, 2017-2032 (USD Million)
  • TABLE 216. Asia-Pacific iPSC Service Market Size, by Reprogramming Service, 2017-2032 (USD Million)
  • TABLE 217. Asia-Pacific iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 218. Asia-Pacific iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 219. Asia-Pacific iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 220. Asia-Pacific iPSC Service Market Size, by Reprogramming Method, 2017-2032 (USD Million)
  • TABLE 221. Asia-Pacific iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 222. Asia-Pacific iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 223. Asia-Pacific iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 224. Asia-Pacific iPSC Service Market Size, by Cell Type, 2017-2032 (USD Million)
  • TABLE 225. Asia-Pacific iPSC Service Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 226. Asia-Pacific iPSC Service Market Size, by Cell Therapy, 2017-2032 (USD Million)
  • TABLE 227. Asia-Pacific iPSC Service Market Size, by Cosmetics Testing, 2017-2032 (USD Million)
  • TABLE 228. Asia-Pacific iPSC Service Market Size, by Disease Modeling, 2017-2032 (USD Million)
  • TABLE 229. Asia-Pacific iPSC Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
  • TABLE 230. Asia-Pacific iPSC Service Market Size, by Regenerative Medicine, 2017-2032 (USD Million)
  • TABLE 231. Asia-Pacific iPSC Service Market Size, by Toxicology Testing, 2017-2032 (USD Million)
  • TABLE 232. Asia-Pacific iPSC Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 233. North America iPSC Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 234. North America iPSC Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 235. North America iPSC Service Market Size, by Banking Service, 2017-2032 (USD Million)
  • TABLE 236. North America iPSC Service Market Size, by Characterization Service, 2017-2032 (USD Million)
  • TABLE 237. North America iPSC Service Market Size, by Differentiation Service, 2017-2032 (USD Million)
  • TABLE 238. North America iPSC Service Market Size, by Genetic Modification Service, 2017-2032 (USD Million)
  • TABLE 239. North America iPSC Service Market Size, by Reprogramming Service, 2017-2032 (USD Million)
  • TABLE 240. North America iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 241. North America iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 242. North America iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 243. North America iPSC Service Market Size, by Reprogramming Method, 2017-2032 (USD Million)
  • TABLE 244. North America iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 245. North America iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 246. North America iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 247. North America iPSC Service Market Size, by Cell Type, 2017-2032 (USD Million)
  • TABLE 248. North America iPSC Service Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 249. North America iPSC Service Market Size, by Cell Therapy, 2017-2032 (USD Million)
  • TABLE 250. North America iPSC Service Market Size, by Cosmetics Testing, 2017-2032 (USD Million)
  • TABLE 251. North America iPSC Service Market Size, by Disease Modeling, 2017-2032 (USD Million)
  • TABLE 252. North America iPSC Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
  • TABLE 253. North America iPSC Service Market Size, by Regenerative Medicine, 2017-2032 (USD Million)
  • TABLE 254. North America iPSC Service Market Size, by Toxicology Testing, 2017-2032 (USD Million)
  • TABLE 255. North America iPSC Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 256. Latin America iPSC Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 257. Latin America iPSC Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 258. Latin America iPSC Service Market Size, by Banking Service, 2017-2032 (USD Million)
  • TABLE 259. Latin America iPSC Service Market Size, by Characterization Service, 2017-2032 (USD Million)
  • TABLE 260. Latin America iPSC Service Market Size, by Differentiation Service, 2017-2032 (USD Million)
  • TABLE 261. Latin America iPSC Service Market Size, by Genetic Modification Service, 2017-2032 (USD Million)
  • TABLE 262. Latin America iPSC Service Market Size, by Reprogramming Service, 2017-2032 (USD Million)
  • TABLE 263. Latin America iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 264. Latin America iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 265. Latin America iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 266. Latin America iPSC Service Market Size, by Reprogramming Method, 2017-2032 (USD Million)
  • TABLE 267. Latin America iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 268. Latin America iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 269. Latin America iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 270. Latin America iPSC Service Market Size, by Cell Type, 2017-2032 (USD Million)
  • TABLE 271. Latin America iPSC Service Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 272. Latin America iPSC Service Market Size, by Cell Therapy, 2017-2032 (USD Million)
  • TABLE 273. Latin America iPSC Service Market Size, by Cosmetics Testing, 2017-2032 (USD Million)
  • TABLE 274. Latin America iPSC Service Market Size, by Disease Modeling, 2017-2032 (USD Million)
  • TABLE 275. Latin America iPSC Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
  • TABLE 276. Latin America iPSC Service Market Size, by Regenerative Medicine, 2017-2032 (USD Million)
  • TABLE 277. Latin America iPSC Service Market Size, by Toxicology Testing, 2017-2032 (USD Million)
  • TABLE 278. Latin America iPSC Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 279. Europe iPSC Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 280. Europe iPSC Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 281. Europe iPSC Service Market Size, by Banking Service, 2017-2032 (USD Million)
  • TABLE 282. Europe iPSC Service Market Size, by Characterization Service, 2017-2032 (USD Million)
  • TABLE 283. Europe iPSC Service Market Size, by Differentiation Service, 2017-2032 (USD Million)
  • TABLE 284. Europe iPSC Service Market Size, by Genetic Modification Service, 2017-2032 (USD Million)
  • TABLE 285. Europe iPSC Service Market Size, by Reprogramming Service, 2017-2032 (USD Million)
  • TABLE 286. Europe iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 287. Europe iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 288. Europe iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 289. Europe iPSC Service Market Size, by Reprogramming Method, 2017-2032 (USD Million)
  • TABLE 290. Europe iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 291. Europe iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 292. Europe iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 293. Europe iPSC Service Market Size, by Cell Type, 2017-2032 (USD Million)
  • TABLE 294. Europe iPSC Service Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 295. Europe iPSC Service Market Size, by Cell Therapy, 2017-2032 (USD Million)
  • TABLE 296. Europe iPSC Service Market Size, by Cosmetics Testing, 2017-2032 (USD Million)
  • TABLE 297. Europe iPSC Service Market Size, by Disease Modeling, 2017-2032 (USD Million)
  • TABLE 298. Europe iPSC Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
  • TABLE 299. Europe iPSC Service Market Size, by Regenerative Medicine, 2017-2032 (USD Million)
  • TABLE 300. Europe iPSC Service Market Size, by Toxicology Testing, 2017-2032 (USD Million)
  • TABLE 301. Europe iPSC Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 302. Middle East iPSC Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 303. Middle East iPSC Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 304. Middle East iPSC Service Market Size, by Banking Service, 2017-2032 (USD Million)
  • TABLE 305. Middle East iPSC Service Market Size, by Characterization Service, 2017-2032 (USD Million)
  • TABLE 306. Middle East iPSC Service Market Size, by Differentiation Service, 2017-2032 (USD Million)
  • TABLE 307. Middle East iPSC Service Market Size, by Genetic Modification Service, 2017-2032 (USD Million)
  • TABLE 308. Middle East iPSC Service Market Size, by Reprogramming Service, 2017-2032 (USD Million)
  • TABLE 309. Middle East iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 310. Middle East iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 311. Middle East iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 312. Middle East iPSC Service Market Size, by Reprogramming Method, 2017-2032 (USD Million)
  • TABLE 313. Middle East iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 314. Middle East iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 315. Middle East iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 316. Middle East iPSC Service Market Size, by Cell Type, 2017-2032 (USD Million)
  • TABLE 317. Middle East iPSC Service Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 318. Middle East iPSC Service Market Size, by Cell Therapy, 2017-2032 (USD Million)
  • TABLE 319. Middle East iPSC Service Market Size, by Cosmetics Testing, 2017-2032 (USD Million)
  • TABLE 320. Middle East iPSC Service Market Size, by Disease Modeling, 2017-2032 (USD Million)
  • TABLE 321. Middle East iPSC Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
  • TABLE 322. Middle East iPSC Service Market Size, by Regenerative Medicine, 2017-2032 (USD Million)
  • TABLE 323. Middle East iPSC Service Market Size, by Toxicology Testing, 2017-2032 (USD Million)
  • TABLE 324. Middle East iPSC Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 325. Africa iPSC Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 326. Africa iPSC Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 327. Africa iPSC Service Market Size, by Banking Service, 2017-2032 (USD Million)
  • TABLE 328. Africa iPSC Service Market Size, by Characterization Service, 2017-2032 (USD Million)
  • TABLE 329. Africa iPSC Service Market Size, by Differentiation Service, 2017-2032 (USD Million)
  • TABLE 330. Africa iPSC Service Market Size, by Genetic Modification Service, 2017-2032 (USD Million)
  • TABLE 331. Africa iPSC Service Market Size, by Reprogramming Service, 2017-2032 (USD Million)
  • TABLE 332. Africa iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 333. Africa iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 334. Africa iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 335. Africa iPSC Service Market Size, by Reprogramming Method, 2017-2032 (USD Million)
  • TABLE 336. Africa iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 337. Africa iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 338. Africa iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 339. Africa iPSC Service Market Size, by Cell Type, 2017-2032 (USD Million)
  • TABLE 340. Africa iPSC Service Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 341. Africa iPSC Service Market Size, by Cell Therapy, 2017-2032 (USD Million)
  • TABLE 342. Africa iPSC Service Market Size, by Cosmetics Testing, 2017-2032 (USD Million)
  • TABLE 343. Africa iPSC Service Market Size, by Disease Modeling, 2017-2032 (USD Million)
  • TABLE 344. Africa iPSC Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
  • TABLE 345. Africa iPSC Service Market Size, by Regenerative Medicine, 2017-2032 (USD Million)
  • TABLE 346. Africa iPSC Service Market Size, by Toxicology Testing, 2017-2032 (USD Million)
  • TABLE 347. Africa iPSC Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 348. Global iPSC Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 349. ASEAN iPSC Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 350. ASEAN iPSC Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 351. ASEAN iPSC Service Market Size, by Banking Service, 2017-2032 (USD Million)
  • TABLE 352. ASEAN iPSC Service Market Size, by Characterization Service, 2017-2032 (USD Million)
  • TABLE 353. ASEAN iPSC Service Market Size, by Differentiation Service, 2017-2032 (USD Million)
  • TABLE 354. ASEAN iPSC Service Market Size, by Genetic Modification Service, 2017-2032 (USD Million)
  • TABLE 355. ASEAN iPSC Service Market Size, by Reprogramming Service, 2017-2032 (USD Million)
  • TABLE 356. ASEAN iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 357. ASEAN iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 358. ASEAN iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 359. ASEAN iPSC Service Market Size, by Reprogramming Method, 2017-2032 (USD Million)
  • TABLE 360. ASEAN iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 361. ASEAN iPSC Service Market Size, by Non-Viral Vector, 2017-2032 (USD Million)
  • TABLE 362. ASEAN iPSC Service Market Size, by Viral Vector, 2017-2032 (USD Million)
  • TABLE 363. ASEAN iPSC Service Market Size, by Cell Type, 2017-2032 (USD Million)
  • TABLE 364. ASEAN iPSC Service Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 365. ASEAN iPSC Service Market Size, by Cell Therapy, 2017-2032 (USD Million)
  • TABLE 366. ASEAN iPSC Service Market Size, by Cosmetics Testing, 2017-2032 (USD Million)
  • TABLE 367. ASEAN iPSC Service Market Size, by Disease Modeling, 2017-2032 (USD Million)
  • TABLE 368. ASEAN iPSC Service Market Size, by Drug Discovery, 2017-2032 (USD Million)
  • TABLE 369. ASEAN iPSC Service Market Size, by Regenerative Medicine, 2017-2032 (USD Million)
  • TABLE 370. ASEAN iPSC Service Market Size, by Toxicology Testing, 2017-2032 (USD Million)
  • TABLE 371. ASEAN iPSC Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 372. GCC iPSC Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 373. GCC iPSC Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 374. GCC iPSC Service Market Size, by Banking Service, 2017-2032 (USD Million)
  • TABLE 375. GCC iPSC Service Market Size, by Characterization Service, 2017-2032 (USD Million)
  • TABLE 376. GCC iPSC Service Market Size, by Differentiation Service, 2017-2032 (USD Million)
  • TABLE 377. GCC iPSC Service Market Size, by Genetic Modification Service, 2017-2032 (USD Million)
  • TABLE 378. GCC iPSC Service Market Size, by Reprogramming Service, 2017-2032 (USD Million)
  • TABLE 379. GCC iPSC Service Market Size, by Integration-Free, 2017-2032 (USD Million)
  • TABLE 380. GCC iPSC Service Market Size, by Non-Viral Vect